Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
62,982.00 +3,811.97 (+6.44%) CMC Crypto 200
1,359.39 +82.41 (+6.45%)
Relmada Therapeutics, Inc. (RLMD)
After hours:
| Previous close | 3.7200 |
| Open | 3.8000 |
| Bid | 3.6400 x 200 |
| Ask | 3.7000 x 100 |
| Day's range | 3.6350 - 3.9300 |
| 52-week range | 2.3600 - 7.2230 |
| Volume | |
| Avg. volume | 198,830 |
| Market cap | 111.041M |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the fourth quarter and full year ended December 31, 2023. The Company will host a conference call today, Tuesday, March 19, at 4:30 PM Eastern Time/1:30 PM Pacific Time.
- PR Newswire
Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2023 after the market close on Tuesday, March 19, 2024. The company will host a corporate update conference call and live audio webcast at 4:30 p.m. Eastern Time on Tuesday, March 19, 2024.
- PR Newswire
Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer will participate in the Leerink Partners Global Biopharma Conference in one-on-one investor meetings, taking place March 11-13, 2024, in Miami Beach, Florida. Please see below for additional details about the event and how to request a one-on-one meeting wit
